GET DAILY SIGNALSOneMedNet (ONMD): Is a +36% Move to $7.00 Realistic?
Key Takeaways
- The $7.00 level is not an analyst consensus but a round-number resistance discussed in public technical commentary.
- From the latest close near $5.14, reaching $7.00 would require roughly a +36% advance, a notable move for this volatile micro-cap.
- OneMedNet has virtually no usable analyst coverage; aggregators showing a $293 average target rely on stale or erroneous pre-merger data that I have excluded.
- Supporting elements include the company’s positioning in AI-ready healthcare imaging data and a recent 23% single-day gain.
- Major risks remain severe, with a going-concern warning, about $358,000 in cash, deep losses, negative book value, and extreme price swings.
- Additional details are available on the company’s Major News, Today's Price Move, Forecast, and Earnings pages.
Analyst Coverage and the $7.00 Target
ONMD — OneMedNet Corporation, a Minnesota-based provider of clinical imaging data and exchange software — lacks meaningful analyst price-target coverage. MarketBeat shows no consensus, and the only recent attributable rating is a sell-type view from Weiss Ratings without a numeric target. Some sites list an average around $293 or a range of $215–$350, but those trace to outdated pre-merger figures and do not apply to a stock trading under $6, so I have set them aside.
With no credible current targets available, the $7.00 figure serves as a technical reference point based on round-number resistance rather than an official forecast. I view it as a level worth monitoring, not a prediction.
Current Position and the Path to $7.00
Shares of OneMedNet closed near $5.14 on November 6, 2026, after rising about 23% that day. The 52-week range spans roughly $3.61 to $23.00. The company is a micro-cap valued around $30 million, remains unprofitable, and reports trailing revenue near $1.46 million against a net loss of about $8.43 million. A move from $5.14 to $7.00 implies a +36% gain, which is sizable in percentage terms yet modest in dollar terms given the stock’s typical daily swings.
Progress toward the level would likely hinge on converting the iRWD platform into larger contracts, strengthening liquidity, and maintaining recent sentiment gains. Absent fundamental improvement, moves have tended to reflect low float and momentum more than earnings results. I also checked this using Tickeron’s AI Screener to compare the stock with peers in the sector.
Factors That Could Support an Advance
- AI healthcare data theme: OneMedNet’s iRWD platform supplies de-identified imaging and clinical data to pharmaceutical, device, and AI clients in an area of structural demand.
- Recent momentum: The 23% single-day gain and breakout above the early-November $4.10–$4.60 range point to renewed speculative interest despite weak fundamentals.
- Low float: With roughly 1.9 million shares available, modest buying can drive outsized percentage moves that might help short-term advances.
Risks That Could Block the Target
- Going-concern warning: Management has expressed substantial doubt about continuing operations, with only about $358,000 in cash and negative equity.
- Ongoing losses: Negative EPS and negative levered free cash flow make it difficult to justify a higher valuation on fundamentals.
- Extreme volatility: The wide 52-week range highlights sharp swings in both directions, so reversals can occur quickly.
- Limited institutional support: Without credible analyst targets or buy ratings, there is little research-driven backing for higher prices.
Technical Levels Worth Watching
Support rests near the $3.61 52-week low, while the recent $4.10–$4.60 zone has acted as near-term support after the November 6 breakout. The $7.00 mark functions as a psychological round-number area well below the prior high near $23.00. Thin trading means these levels can produce gaps and sharp moves rather than orderly behavior.
Time Horizon and Items to Monitor
Because no formal analyst targets exist, the $7.00 level is best seen as a nearer-term technical milestone rather than a 12-month objective. I am watching the next earnings report, cash position, any capital-raising moves, new data-licensing contracts, and updates on the going-concern language. Shifts in float, insider or institutional activity, and broader risk appetite in small-cap and AI-themed names also matter.
Using AI Tools in My Research
In my own process, I frequently rely on Tickeron’s AI Daily Buy/Sell Signals to track momentum shifts across volatile names like this one. The platform applies AI to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical and market data. For micro-caps with limited coverage, these signals help surface changes in trend more efficiently than manual checks alone and serve as a useful complement to traditional analysis.
Final Assessment
Can ONMD reach $7.00? The level is a technical reference rather than an analyst consensus and would require a +36% rise from roughly $5.14. Momentum and the AI healthcare data theme offer some support, yet the going-concern warning, limited cash, deep losses, and lack of analyst backing present real hurdles. The distance between the $3.61 low and the $23.00 high underscores the stock’s unpredictability. I treat $7.00 as a level to observe rather than a forecast and will continue to follow earnings, liquidity, and contract or financing updates before drawing conclusions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
ONMD in -5.38% downward trend, falling for three consecutive days on October 30, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONMD declined for three days, in 218 of 241 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
ONMD broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ONMD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ONMD's RSI Indicator exited the oversold zone, 18 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 35 of 57 cases where ONMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 61%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ONMD as a result. In 41 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
The Moving Average Convergence Divergence (MACD) for ONMD just turned positive on October 21, 2026. Looking at past instances where ONMD's MACD turned positive, the stock continued to rise in 30 of 57 cases over the following month. The odds of a continued upward trend are 53%.
ONMD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +43.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONMD advanced for three days, in 113 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. ONMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ONMD's P/B Ratio (-86.621) is very low in comparison to the industry average of (4.477). P/E Ratio (-3.024) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. ONMD's P/S Ratio (23.529) is slightly higher than the industry average of (6.065).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement